tetano
Editor, Senior Moderator
Jpn J Infect Dis
. 2020 Nov 30.
doi: 10.7883/yoken.JJID.2020.463. Online ahead of print.
Association of interleukin-6 level with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19)
Jiali Zhou[SUP] 1 [/SUP], Wenbo He, Jingyu Liang[SUP] 1 [/SUP], Lang Wang[SUP] 1 [/SUP], Xiaomei Yu[SUP] 1 [/SUP], Mingwei Bao[SUP] 1 [/SUP], Huafen Liu[SUP] 1 [/SUP]
Affiliations
Abstract
The prognostic value of interleukin-6 in COVID-19 needs to be clarified. In this retrospective study, COVID-19 patients treated in Renmin Hospital of Wuhan University from Jan 7 to Feb 8, 2020 with measurements of serum IL-6 levels within 1 week after admission were included. Data regarding demographics, clinical characteristics, laboratory tests, complications and outcomes were collected and analyzed. Sixty-six patients included (31 females) were divided into normal group (serum IL-6 < 10pg/mL, n=35) and abnormal group (serum IL-6 ≥ 10pg/mL, n=31). Compared with normal group, the incidences of critical cases (P<0.001), ARDS (P=0.001), acute cardiac injury (P=0.002), cardiac insufficiency (P=0.039), mechanical ventilation rate (P=0.002) and the mortality (P=0.021) were significantly increased in abnormal group. Serum IL-6 concentration was an independent predictor for a fatal outcome (P=0.04). The optimal cutoff value of serum IL-6 concentration for predicting fatal outcomes was 26.09 pg/mL (P < 0.001). In COVID-19, elevated serum IL-6 levels were associated with critical illness, usage of mechanical ventilation and complications including heart injury and ARDS, and could predict a fatal outcome. Early detection of serum IL-6 levels after admission would be necessary in COVID-19 patients.
Keywords: coronavirus disease; inflammation; interleukin-6.
. 2020 Nov 30.
doi: 10.7883/yoken.JJID.2020.463. Online ahead of print.
Association of interleukin-6 level with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19)
Jiali Zhou[SUP] 1 [/SUP], Wenbo He, Jingyu Liang[SUP] 1 [/SUP], Lang Wang[SUP] 1 [/SUP], Xiaomei Yu[SUP] 1 [/SUP], Mingwei Bao[SUP] 1 [/SUP], Huafen Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 33250487
- DOI: 10.7883/yoken.JJID.2020.463
Abstract
The prognostic value of interleukin-6 in COVID-19 needs to be clarified. In this retrospective study, COVID-19 patients treated in Renmin Hospital of Wuhan University from Jan 7 to Feb 8, 2020 with measurements of serum IL-6 levels within 1 week after admission were included. Data regarding demographics, clinical characteristics, laboratory tests, complications and outcomes were collected and analyzed. Sixty-six patients included (31 females) were divided into normal group (serum IL-6 < 10pg/mL, n=35) and abnormal group (serum IL-6 ≥ 10pg/mL, n=31). Compared with normal group, the incidences of critical cases (P<0.001), ARDS (P=0.001), acute cardiac injury (P=0.002), cardiac insufficiency (P=0.039), mechanical ventilation rate (P=0.002) and the mortality (P=0.021) were significantly increased in abnormal group. Serum IL-6 concentration was an independent predictor for a fatal outcome (P=0.04). The optimal cutoff value of serum IL-6 concentration for predicting fatal outcomes was 26.09 pg/mL (P < 0.001). In COVID-19, elevated serum IL-6 levels were associated with critical illness, usage of mechanical ventilation and complications including heart injury and ARDS, and could predict a fatal outcome. Early detection of serum IL-6 levels after admission would be necessary in COVID-19 patients.
Keywords: coronavirus disease; inflammation; interleukin-6.